Convergent evolution and topologically disruptive polymorphisms among multidrug-resistant tuberculosis in Peru

Louis Grandjean1,2,3,4*, Robert H. Gilman3,5, Tomatada Iwamoto6, Claudio U. Köser7, Jorge Coroneo3, Mirko Zimic3, M. Estee Török4, Diepreye Ayabina8, Michelle Kendall8, Christophe Fraser9, Simon Harris4, Julian Parkhill4, Sharon J. Peacock4,10, David A. J. Moore10, Caroline Colijn8

1 University College London, Institute of Child Health, London, United Kingdom, 2 Academic Health Sciences Centre, Imperial College, London, United Kingdom, 3 Universidad Peruana Cayetano Heredia, Avenida Honorio Delgado, San Martin de Porras, Lima, Peru, 4 Wellcome Trust Sanger Institute, Genome Campus, Hinxton, Cambridge, United Kingdom, 5 Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States of America, 6 Department of Infectious Diseases, Kobe Institute of Health, Chuo-ku, Kobe, Japan, 7 Department of Medicine, University of Cambridge, Cambridge, United Kingdom, 8 Faculty of Natural Sciences, Department of Mathematics, Imperial College London, London, United Kingdom, 9 Department of Infectious Diseases Epidemiology, Imperial College, London, United Kingdom, 10 London School of Tropical Medicine and Hygiene, London, United Kingdom

* l.grandjean@imperial.ac.uk

Abstract

Background

Multidrug-resistant tuberculosis poses a major threat to the success of tuberculosis control programs worldwide. Understanding how drug-resistant tuberculosis evolves can inform the development of new therapeutic and preventive strategies.

Methods

Here, we use novel genome-wide analysis techniques to identify polymorphisms that are associated with drug resistance, adaptive evolution and the structure of the phylogenetic tree. A total of 471 samples from different patients collected between 2009 and 2013 in the Lima suburbs of Callao and Lima South were sequenced on the Illumina MiSeq platform with 150bp paired-end reads. After alignment to the reference H37Rv genome, variants were called using standardized methodology. Genome-wide analysis was undertaken using custom written scripts implemented in R software.

Results

High quality homoplastic single nucleotide polymorphisms were observed in genes known to confer drug resistance as well as genes in the Mycobacterium tuberculosis ESX secreted protein pathway, pks12, and close to toxin/anti-toxin pairs. Correlation of homoplastic variant sites identified that many were significantly correlated, suggestive of epistasis. Variation in genes coding for ESX secreted proteins also significantly disrupted phylogenetic
structure. Mutations in ESX genes in key antigenic epitope positions were also found to disrupt tree topology.

Conclusion
Variation in these genes have a biologically plausible effect on immunogenicity and virulence. This makes functional characterization warranted to determine the effects of these polymorphisms on bacterial fitness and transmission.

Introduction
The World Health Organization estimates that multidrug-resistant tuberculosis causes 500 deaths and 1300 new infections each day [1]. Understanding the genetic basis of tuberculosis drug resistance, host immune evasion and bacterial phenotype is important to inform the development of new diagnostic, treatment and preventive strategies. Identifying convergent evolution in multidrug-resistant tuberculosis may uncover how Mycobacterium tuberculosis is adaptively evolving to evade host immunity and antibiotic chemotherapy. Determining which variant sites are most disruptive of phylogenetic structure could also uncover important genotypic influences on phenotype.

Homoplasy is defined as the emergence of identical traits or characters occurring independently in different clades that are not present in their common ancestor [2]. Homoplastic events are often associated with adaptive advantages, a frequently cited example being the independent evolution of the eye across multiple different species [3]. Analyses of genome wide data looking for homoplasious signals have already led to the identification of genes associated with echo location in mammals [4], caffeine production in coffee and tea [5], and the adaptation of Pseudomonas to the human lung in cystic fibrosis [6]. Homoplastic mutations among drug resistant M. tuberculosis may code for drug resistance or mechanisms of immune subversion [7,8].

Only a few studies have examined M. tuberculosis strain collections for evidence of homoplasy. Casali et al [9] identified a set of homoplastic mutations among a large collection of 1000 prospectively collected strains in Samara Oblast, while Farhat et al [7] in a smaller dataset of 123 strains compared the occurrence of multiple independent mutations in MDRTB strains to that among drug susceptible strains. Others have screened a selected set of genes encoding surface proteins for homoplasy to test the hypothesis that mutations in these surface proteins at the interface with the human immune system lead to significant adaptive advantage [8]. No studies have examined the correlation between homoplasic sites or identified variant sites that particularly influence phylogenetic structure.

In order to identify homoplasy, topologically disruptive polymorphisms and evidence of epistasis we sequenced the genomes of 471 predominantly multidrug-resistant tuberculosis isolates collected in the suburbs of metropolitan Lima, Peru.

Results and discussion
Patient demographics. The median age of recruited patients was 30 years (IQR 23–42) with an HIV prevalence of 4% (19/469) and a smear positivity percentage of 90% (416/469), S1 Table.
level in Lima (Fig 1) supported by high (>99%) bootstrap probabilities and also by principle component analysis. Samples were predominantly from lineage 4 (Euro-American) which comprised 54% (255/469) LAM (Latin American Mediterranean), 17% (81/469) Haarlem, 10% (47/469) T Clade and 10% (47/469) other small clades (including X, S and other T-type MIRU-spoligotypes). A total of 34 (7%) were from the lineage 2 Beijing family and the remainder of the data-set included 3 Mycobacterium caprae strains, one Mycobacterium bovis strain and one East Asian Indian Manilla (EIA2) strain (Table 1).

Phylogenetic comparison of 15-loci MIRU-VNTR with whole genome sequencing

At high resolution when the sub-clades of the LAM clade as defined by MIRU-VNTR were compared to whole genome sequence defined clades (Fig 2), significant disagreement in clade topology was observed. This highlights the unreliable nature of defining a sub-clade based on MIRU-VNTR alone. MIRU derived trees correlated better with the whole genome trees than trees constructed from concatenated MIRU-spoligotypes and much better than trees made from spoligotyping alone (S1 Fig).
| Table 1. Table of demographics.                  | Number | Proportion |
|------------------------------------------------|--------|------------|
| Whole Genomes Sequenced                        | 471    | 100%       |
| Metadata Available (Denominator)               | 469    | 99%        |
| **Sex**                                        |        |            |
| Male                                           | 288    | 61%        |
| Female                                         | 179    | 38%        |
| Unknown                                        | 2      | 1%         |
| **Age Median (IQR) Overall**                   | 0 (23–42) | -         |
| <10                                            | 0      | 0%         |
| 10–<20                                         | 49     | 10%        |
| 20–<30                                         | 174    | 37%        |
| 30–<40                                         | 104    | 22%        |
| 40–<50                                         | 54     | 12%        |
| 50–<60                                         | 38     | 8%         |
| >60                                            | 37     | 8%         |
| Unknown                                        | 13     | 3%         |
| **Ziehl Neelsen Smear Status**                 |        |            |
| Positive                                       | 416    | 89%        |
| Negative                                       | 46     | 10%        |
| Unknown                                        | 7      | 1%         |
| **Previous TB Disease**                        |        |            |
| Yes                                            | 298    | 64%        |
| No                                             | 171    | 36%        |
| Unknown                                        | 0      | 0%         |
| **HIV Status**                                 |        |            |
| Positive                                       | 19     | 4%         |
| Negative                                       | 450    | 96%        |
| Unknown                                        | 0      | 0%         |
| **Drug Resistance Profile**                    |        |            |
| Susceptible<sup>1</sup>                        | 26     | 6%         |
| Rifampicin Resistant                           | 33     | 7%         |
| Isoniazid Resistant                            | 97     | 21%        |
| Multidrug Resistant                            | 311    | 66%        |
| MIRU-Spoligotype Available                     | 240    | 52%        |
| **Clade**                                      |        |            |
| Latin American Mediterranean                  | 255    | 54%        |
| Haarlem                                        | 81     | 17%        |
| Beijing                                       | 34     | 7%         |
| T                                              | 47     | 10%        |
| Mycobacterium caprae                           | 3      | <1%        |
| Mycobacterium bovis                            | 1      | < 1%       |
| East Asian Indian                              | 1      | <1%        |
| Other Small Clades<sup>2</sup>                 | 47     | 10%        |

<sup>1</sup>Susceptible to Rifampicin and Isoniazid.

<sup>2</sup>Comprised the MIRU defined ‘S’ family, ‘X’ family and ‘T’ family strains.

https://doi.org/10.1371/journal.pone.0189838.t001
Homoplastic non-synonymous polymorphisms

Many of the known drug resistance mutations were observed to occur homoplastically across the phylogeny (S2 Table). These mutations have been widely reported elsewhere [10]. A phylogeny of the study strains together with the sites of homoplastic polymorphisms is provided in Fig 3.

The Rv2828c non-synonymous mutation Thr141Met is particularly interesting as a separate intergenic homoplastic polymorphism was also identified in the promoter region 2bp upstream of the start of Rv2828c (position 3136343). This gene has not as yet been implicated with drug resistance or virulence, however the Rv2828c gene is adjacent to a toxin antitoxin (TA) system vapC22 (Rv2829c) vapB22 (Rv2830c) which has been demonstrated to limit growth of M. smegmatis [11]. Toxin gene products of vapB and vapC block M. tuberculosis translation via RNA cleavage thereby slowing down the replication rate facilitating successful latent infection [11,12]. Many antibiotics target bacterial growth, making slowly replicating bacteria more refractory to treatment [13]. Ramage et al highlight that the significant
expansion of TA systems relative to the last common ancestor of *M. tuberculosis* suggesting an important role for these systems in *M. tuberculosis* evolution [11].

The non-synonymous homoplastic polymorphism in *esxI* occurred in the epitope coding region at position 1160767 (Ser23Leu). This polymorphism has been described by Upleker et al [14] as critical to immunogenicity and therefore likely to confer a functionally beneficial adaptive advantage.

The *lldD2* non-synonymous single nucleotide polymorphism Val3Ile (at position 2123153) occurred independently 12 times and expanded to a total of 70 strains at the tips of the tree (a second non-synonymous homoplastic *lldD2* Val253Met variant at position 2122403 was also identified). The *lldD2* gene is a putative lactate dehydrogenase. Osorio et al [8] identified this polymorphism when evaluating genes encoding membrane proteins for diversifying selection. They speculated that mutations in this gene could represent a metabolic adaptation to host environment such as anaerobic conditions. One synonymous polymorphism also occurred homoplastically in *Rv1873*, a gene of unknown function located adjacent to *lldD2* [15].
Homoplastic intergenic polymorphisms

The most homoplastic intergenic polymorphism (occurring 13 times independently and expanding to 64 strains at the tips of the tree) arose 15bp upstream (position 1673433) of fabG1 in the promoter region [16]. This gene is associated with isoniazid resistance as it can act as an alternative promoter for inhA [17].

Homoplastic synonymous polymorphisms in ESX genes

Emerging evidence suggests that synonymous sites may also be under selection because of adaptive changes in gene expression via transcription factor binding or mRNA stability [18]. The ESAT-6 like ESX proteins were over represented among the synonymous polymorphisms identified in this analysis. The family of proteins coded by these genes are the most immunodominant of M. tuberculosis antigens. A synonymous esxK mutation (position 1340675 A to G) occurred independently on 9 occasions expanding to 84 strains at the tips of the tree. This mutation fell in the middle of a transcription factor binding hotspot that has been demonstrated to bind 10 different gene regulators [19]. Only 2.5% of the genome acts as a binding site for multiple transcription factors making these regions highly likely to influence gene expression. Supporting the importance of the esx genes in immunogenicity, Villareal and colleagues [20] have already demonstrated substantial antigen-specific IFN-γ spot-forming cells to all esx antigens together with a maintained memory response. In addition, none of esxO, esxV, esxP, esxW, esxA, and esxB are present in avirulent BCG [21]. The conservation of silent as well as nonsynonymous SNPs between paralogs and orthologs of the ESX family, as seen in esxP and esxM, respectively, suggests that even minor variation within these families could significantly alter the expression of these proteins [14]. Uplekar et al also suggested that sequence changes in ESX genes are likely to lead to immune variation and found evidence of intra-genomic recombination as a potential source of variation in these genes. Skjot and colleagues hypothesized that the amino acid substitutions encoded by the duplicated genes for the ESAT-6 protein family may allow for antigenic drift, wherein the regulated expression of functionally similar protein homologs that differ in their immunodominant epitopes result in antigen variation and immune system escape [22].

Other homoplastic synonymous polymorphisms that occurred in transcription factor binding hotspots included those in esxL (3 homoplastic sites, C>G at position 1341052), esxO (2 homoplastic sites, C>G at position 2626103) and Rv1873 (a gene upstream of lldD2, 3 homoplastic sites, A>C at position 2123190). The genes esxL, esxM and esxN also demonstrated synonymous polymorphism homoplasy albeit with two ancestral homoplastic mutations only. Two homoplastic synonymous sites were identified in the gene pks12 also identified as homoplastic by Farhat et al [7]. This gene is the largest in the Mycobacterium tuberculosis genome and is involved in pathogenesis by dimycocerosyl phthiocerol synthesis [23].

The esx genes also featured in the phyC output (S3 Table) with mutations in esxK, esxN and esxV also identified as being homoplastic. The homoplastic synonymous polymorphism in esxN identified by phyC also occurred in the epitope coding region of esxN at position 2030950.

Homoplastic mutations in lldD2, pks12, Rv2828c, Rv0277 were also confirmed with this technique. Additional homoplastic mutations of interest identified with phyC but not with the accelerated transformation analysis included the mutation occurring in Rv2571c, a gene located adjacent to aspS, which is involved in the M. tuberculosis translational pathway.

Correlation between homoplastic sites

Blocks of correlation indicative of epistatic interaction were identified between homoplastic polymorphisms (S2 Fig). Notably the homoplastic mutations in rpsL, Rv2082, lppB, lldD2 and
the intergenic region around position 3841670 were all significantly positively correlated. Similarily, the \textit{pks12} gene mutation was positively correlated with mutations in \textit{Rv2082} and intergenic regions 3067969, 3122583, 3232711 and 3820553. A strong negative correlation was observed between mutations in \textit{pks12} and \textit{Rv2082} as well as between \textit{esxV} with intergenic mutation at position 3738660. Unexpectedly no correlation was observed between \textit{rpoC} mutations and \textit{rpoB} mutations. Mutations in \textit{rpoC} have been demonstrated to compensate for mutations in \textit{rpoB} in vitro and therefore we hypothesized that homoplastic mutations in these two genes may be correlated \cite{24}. A similar lack of correlation was seen in other well documented drug resistance mutations (\textit{katG}, \textit{gyrA}, \textit{inhA}) suggesting that there is not a homoplastic compensatory mechanism for the drug resistance mutations in these genes.

Topologically disruptive sites. Only 2.19\% (382/17476) of all variant sites were found to disrupt phylogenetic structure (S4 Table, Fig 4). The variant site that most affected phylogenetic structure was a non-synonymous single nucleotide polymorphism observed in \textit{esxI} at position 1160776 (Gln20Leu). This polar to non-polar substitution occurred right in the middle of the \textit{esxI} epitope coding region making it likely to influence the immune response to \textit{M. tuberculosis} infection. The paralogous nature of the \textit{esxI} gene with repeating regions up and downstream does however make this mutation less reliable when called by 150bp read sequencing. It is therefore necessary to repeat and confirm this observation using longer read sequencing platforms. The tree difference algorithm also identified the non-synonymous Leu23Ser mutation at the antigenically critical position in the middle of the epitope region of \textit{esxL} at position 1341081. Once again this was not picked up by either Sanger or phyC homoplasy software. This supports our hypothesis that phylogenetically disruptive polymorphisms may affect
pheno\textsuperscript{\textregistered}type; three of the fifty most informative sites also included \textit{rpoB}, \textit{katG} and \textit{embB} mutations, well documented to have phenotypic consequence in drug resistance.

Genome wide association corrected for phylogenetic structure by principal component analysis

Correcting for principal components significantly reduced the background noise in the Manhattan plots demonstrating the key polymorphisms involved in second line drug resistance (S3 and S4 Figs). Genome wide analysis for sputum smear grade (positive vs negative), gender, HIV status and previous treatment did not uncover any significant polymorphisms.

Conclusion

This study has identified the presence of a set of convergent homoplastic polymorphisms among a collection of 471 predominantly multidrug-resistance tuberculosis strains in Peru. Homoplasy is highly associated with beneficial adaptive evolution as evidenced by the confirmation of many homoplastic drug resistance mutations and mutations in the highly immunogenic secreted protein ESX gene family. Mutations in the ESX genes may therefore have implications for vaccine development, while designing drugs to target these gene products may help to prevent the consequences of adaptive evolution or immune evasion of multi-drug resistant \textit{M. tuberculosis}. A non-synonymous Leu23Ser mutation at the antigenically critical position in the middle of the epitope region of \textit{esxL} at position 1341081 was identified by the tree difference algorithm. This lends weight to our hypothesis that polymorphisms that affect tree topology can have phenotypically significant consequences. Functional and longer sequencing read confirmation of the homoplastic and topologically disruptive polymorphisms identified here is therefore warranted as well as the use of this technique to identify informative sites in other organisms.

Materials and methods

Ethics approval and consent to participate. Ethical approval for sample collection and processing was obtained from the IRB of the Universidad Peruana Cayetano Heredia as part of previously published studies [25,26] and institutional approval was obtained from the Peruvian Ministry of Health. Individual patient consent was not sought as the data was collected and analysed anonymously.

Field methods, culture techniques and sample selection

Collection of patient metadata, sputum samples, culture techniques, DNA extraction, MIRU typing and spoligotyping were undertaken as previously described [25,26]. Briefly, samples were selected from two large studies undertaken in the regions of Callao (population size 800,000) and Lima South (population size 1,200,000). The first study (“population level study”) undertaken between 2008–2010 sampled all patients presenting to tuberculosis clinics and hospitals in these areas as part of the population level implementation of Microscopic Observed Drug Susceptibility (MODS) testing [27,28]. The second study (“household follow-up study”) followed 213 households with an MDRTB index case and 487 households with a DSTB index case in the same study area over a period of 3 years between 2010–2013.

Population level study sampling

Samples were collected from 2086 unselected unique patients presenting with symptoms of tuberculosis across this study area. All study samples were genotyped with 15-loci MIR-U-VNTR and spoligotyping. At least one strain was selected for whole genome sequencing.
from every MIRU-VNTR and spoligotype defined cluster in order to sample a representative selection of total population genetic diversity, maximize genomic variability and to improve analytical power. A total of 198 samples were selected from MIRU-spoligotype defined clusters as well as 87 samples from unique MIRU-spoligotypes. Metadata was gathered using a structured questionnaire that was completed at the time of sputum collection.

Household study sampling
The second study recruited unselected newly diagnosed multidrug-resistant tuberculosis patients in the same study areas as part of a 3-year long household follow-up study conducted between 2010–2013. This study recruited a total of 213 MDRTB patients of which 186 multidrug-resistant tuberculosis strains were selected at random to contribute to this analysis. Metadata was collected in a structured questionnaire completed at recruitment for household follow-up.

All tuberculosis patients in Peru are tested for HIV, so this data was available from the patient records at the time of recruitment to both studies. Sputum samples from all patients in both studies were transported to the regional reference laboratories and processed both on liquid (MODS) and solid Ogawa media. An aliquot of each positive culture was sub-cultured at Universidad Peruana Cayetano Heredia and spoligotyping was performed [29] after DNA extraction [30]. DNA was sent to the Kobe Institute, Japan for 15-loci MIRU VNTR typing [31]. Any drug resistant sample (resistant to rifampicin or isoniazid) based on MODS was retested at the national reference laboratory using the proportions method on agar.

Genome sequence quality control
We prepared Illumina sequencing libraries with a 450 bp insert size, using instructions in the manufacturer’s protocols, and then undertook sequencing on an Illumina HiSeq2000 with paired-end reads of length of 100 bp. To this end we multiplexed 96 samples per lane to attain an average depth of coverage of ~97.17-fold. We confirmed the species in the short reads using Kraken [32]. We assembled paired end sequence reads with an improved assembly pipeline [33], based on Velvet [34]. A list of isolates and their accession numbers in the European Nucleotide Archive is provided in S4 Table (project number: ERP004677). We mapped short reads to the corrected H37Rv reference genome available from Casali et al. [35] genome.cshlp.org/content/suppl/2012/02/01/gr.128678.111.DC1/1_H37RvQM_embl.txt. In doing so, we employed SMALT v0.7.4 (www.sanger.ac.uk/science/tools/smal t-0) using maximum and minimum inserts sizes of 1000 and 50, respectively. To annotate SNPs, we used SAMtools mpileup [36] and BCFtools, as it is described by Harris et al [37]. We included SNPs that were covered by at least two forward and two reverse short paired end reads [38]. A minimum base call quality of 50 and a minimum mean squared mapping quality of 30 to call a SNP were used. Furthermore, the SNPs at sites with heterogeneous mapping where less than 75% of reads at that site covered the SNP were excluded from the analysis [37]. We obtained the multiple alignment by generating pseudo-sequences, after ignoring the small indels.

Phylogenetic analysis and ancestral state reconstruction
Maximum likelihood, parsimony and neighbour joining phylogenies were constructed with concatenated SNPs from the whole genome sequence data using R software (R Foundation for Statistical Computing, Vienna, Austria 2011, www.R-project.org) with packages “adegenet”, “phangorn” [39] as well as RAxML [40]. Whole genome sequence clades were defined as having bootstrap confidence value of 99 or higher [41], these clades were independently confirmed using principal component analysis. Clades were named using the corresponding
MIRU-VNTR and spoligotype independently by the Institut Pasteur Guadeloupe according to published protocols (www.miru-vntrplus.org and www.pasteur-guadeloupe.fr:8081/SITVIT_ONLINE) [42]. Ancestral state reconstruction was undertaken using maximum parsimony, likelihood and Bayesian approaches.

**Identification and correlation of homoplastic variants**

Homoplastic variants were identified by two techniques; 1) a Sanger in-house software that applied the accelerated transformation algorithm to a maximum parsimony tree and 2) phyC software [7] that pre-specified drug resistant and drug susceptible states and compared the occurrence of independent ancestral changes between the two groups. Both methods counted the number of independent occasions in which an ancestral base was different to the descendant base at any given site in the tree. The phyC method also calculated the Fisher’s exact statistic for the comparison of the number of homoplastic events that occurred in drug susceptible versus drug resistant strains. Given that some of the ESX genes are paralogous we also visually inspected the SNP calls within ESX genes to ensure that the mapping was accurate and coverage reliable enough to call the SNP. Correlation between homoplastic variant sites was undertaken in R using the cor.table function from the picante package.

**Principal component analysis genome wide association**

Genome wide analysis with Bonferroni correction and correction for underlying genetic structure by principal components was performed for the following variables; resistance to first and second line drugs (kanamycin, ciprofloxacin, capreomycin), sputum smear status, gender, HIV status and previous treatment history using the function dapc from the package adegenet [43,44].

**Comparing whole genome, MIRU, MIRU-spoligotype dendrograms**

The correlation between whole genome, MIRU, MIRU-Spoligotype derived dendrograms was determined using the R program “Dendextend”. Co-phenetic correlations were obtained as per the Dendextend reference manual [45].

**Determining polymorphisms most disruptive of phylogenetic structure**

Kendall et al [46,47] proposed a tree comparison method for determining variant sites most influential of tree structure in which a “reference” tree is constructed from the whole alignment, then compared to “experimental” trees built with the variant site in question removed. We used this method to detect phylogenetically informative and therefore potentially biologically informative polymorphisms in our alignment. This method will detect Homoplasy as does phyC and the Sanger software cited above, however it will also identify single ancestral sites that have particular influence on tree structure.

We noted that in a random sample of 100 single sites that belonged to blocks of 10 adjacent alignment sites which when removed did not cause a change in the initial screening, none were found to cause a change in the tree. It is widely accepted that tuberculosis does not undergo recombination, and in the absence of recombination, under circumstances with sufficient genetic diversity to recreate high-quality phylogenetic trees, removal of a single variable site from an alignment of ~20,000 variable sites should not affect the topology of the reconstructed phylogeny. While the information in all variable sites is pooled to reconstruct the phylogeny, we term sites whose removal led to an altered tree topology “phylogenetically disruptive”.

PLOS ONE | https://doi.org/10.1371/journal.pone.0189838 | December 27, 2017
Using RAxML 7.2.4 [40] with the GTRCAT model of rate heterogeneity [48] to construct our trees, we created a reference tree from all 20976 variant sites. The same settings were then used to create trees from the alignment with the site in question removed. For an initial screening and to minimize computational time we removed blocks of ten sites from the alignment at a time. We compared the trees as per Kendall et al [46], using function refTreeDist from R package treescape [49]. We found that around 10% of the blocks of 10 variant sites, when removed, produced a tree with a different topology from the reference tree. We then re-ran the method, removing a single site of the alignment at a time, each belonging to a block of 10 that caused a change in the first run.

**Supporting information**

S1 Fig. The cophenetic correlation coefficient of whole genome sequence, MIRU, MIRU and spoligotype combined (MIRU Spol) and spoligotype dendrograms.

(SPS)

S2 Fig. Hotspots of correlation between homoplastic sites. White and yellow indicate significant positive correlation (p<0.05) while red indicates significant negative correlation (p<0.05).

(SPS)

S3 Fig. Genome wide analysis with correction for population structure by principle components and Bonferroni correction for rifampicin, isoniazid, pyrazinamide and ethambutol drug resistance polymorphisms in *M. tuberculosis*.

(SPS)

S4 Fig. Genome wide analysis with correction for population structure by principle components and Bonferroni correction for streptomycin, kanamycin, capreomycin and ciprofloxacin drug resistance polymorphisms in *M. tuberculosis*.

(SPS)

S1 Table. Study metadata.

(XLSX)

S2 Table. The most homoplastic polymorphisms.

(DOCX)

S3 Table. Homoplastic polymorphisms detected by phyC.

(DOCX)

S4 Table. The most topologically influential polymorphisms.

(DOCX)

S5 Table. Accession numbers for genomes sequenced.

(DOCX)

**Acknowledgments**

Dr Gwenan Knight for insightful comments. Luz Caviedes whose passion for science and teaching will always remain with us.
Author Contributions

Conceptualization: Louis Grandjean, Robert H. Gilman, Tomatada Iwamoto, Claudio U. Köser, Jorge Coronel, Mirko Zimic, M. Estee Török, Diepreye Ayabina, Michelle Kendall, Christophe Fraser, Simon Harris, Julian Parkhill, Sharon J. Peacock, David A. J. Moore, Caroline Colijn.

Data curation: Louis Grandjean, Robert H. Gilman, Tomatada Iwamoto, Claudio U. Köser, Jorge Coronel, Mirko Zimic, M. Estee Török, Diepreye Ayabina, Michelle Kendall, Christophe Fraser, Simon Harris, Julian Parkhill, Sharon J. Peacock, David A. J. Moore, Caroline Colijn.

Formal analysis: Louis Grandjean, Tomatada Iwamoto, Claudio U. Köser, Jorge Coronel, Mirko Zimic, M. Estee Török, Diepreye Ayabina, Michelle Kendall, Christophe Fraser, Simon Harris, Julian Parkhill, Sharon J. Peacock, David A. J. Moore, Caroline Colijn.

Funding acquisition: Louis Grandjean, Robert H. Gilman, Tomatada Iwamoto, Claudio U. Köser, M. Estee Török, Michelle Kendall, Julian Parkhill, Sharon J. Peacock, David A. J. Moore, Caroline Colijn.

Investigation: Louis Grandjean, Robert H. Gilman, Tomatada Iwamoto, Claudio U. Köser, Jorge Coronel, Mirko Zimic, M. Estee Török, Diepreye Ayabina, Michelle Kendall, Christophe Fraser, Simon Harris, Julian Parkhill, Sharon J. Peacock, David A. J. Moore, Caroline Colijn.

Methodology: Louis Grandjean, Robert H. Gilman, Tomatada Iwamoto, Claudio U. Köser, Jorge Coronel, Mirko Zimic, M. Estee Török, Diepreye Ayabina, Michelle Kendall, Christophe Fraser, Simon Harris, Julian Parkhill, Sharon J. Peacock, David A. J. Moore, Caroline Colijn.

Project administration: Louis Grandjean, Robert H. Gilman, Tomatada Iwamoto, Claudio U. Köser, Mirko Zimic, M. Estee Török, Diepreye Ayabina, Michelle Kendall, Christophe Fraser, Simon Harris, Julian Parkhill, Sharon J. Peacock, David A. J. Moore, Caroline Colijn.

Resources: Louis Grandjean, Tomatada Iwamoto, Claudio U. Köser, Jorge Coronel, Mirko Zimic, M. Estee Török, Simon Harris, Julian Parkhill, Sharon J. Peacock, David A. J. Moore, Caroline Colijn.

Software: Louis Grandjean, Diepreye Ayabina, Julian Parkhill, Sharon J. Peacock, Caroline Colijn.

Supervision: Louis Grandjean, Robert H. Gilman, Tomatada Iwamoto, Christophe Fraser, Simon Harris, Julian Parkhill, Sharon J. Peacock, David A. J. Moore, Caroline Colijn.

Validation: Louis Grandjean, Tomatada Iwamoto, Claudio U. Köser, Jorge Coronel, Mirko Zimic, M. Estee Török, Diepreye Ayabina, Michelle Kendall, Julian Parkhill, Sharon J. Peacock, David A. J. Moore, Caroline Colijn.

Visualization: Louis Grandjean, Robert H. Gilman, Claudio U. Köser, Jorge Coronel, Diepreye Ayabina, Michelle Kendall, Christophe Fraser, Simon Harris, Julian Parkhill, Sharon J. Peacock, David A. J. Moore, Caroline Colijn.

Writing – original draft: Louis Grandjean, Robert H. Gilman, Tomatada Iwamoto, Claudio U. Köser, Jorge Coronel, Mirko Zimic, M. Estee Török, Diepreye Ayabina, Michelle Kendall, Christophe Fraser, Simon Harris, Julian Parkhill, Sharon J. Peacock, David A. J. Moore, Caroline Colijn.
Adaptive evolution in multidrug-resistant tuberculosis

Writing – review & editing: Louis Grandjean, Robert H. Gilman, Tomatada Iwamoto, Claudio U. Köser, Jorge Coronel, M. Estee Török, Diepreye Ayabina, Michelle Kendall, Christopher Fraser, Simon Harris, Julian Parkhill, Sharon J. Peacock, David A. J. Moore, Caroline Colijn.

References

1. WHO | Global tuberculosis report 2016 [Internet]. WHO. [cited 2017 Apr 6]. Available from: http://www.who.int/tb/publications/global_report/en/

2. Wood TE, Burke JM, Rieseberg LH. Parallel genotypic adaptation: when evolution repeats itself. Genetica. 2005; 123:157–70. PMID: 15881688

3. Piatigorsky J. A Genetic Perspective on Eye Evolution: Gene Sharing, Convergence and Parallelism. Evol. Educ. Outreach. 2008; 1:403–14.

4. Parker J, Tsagkogeorga G, Cotton JA, Liu Y, Provero P, Stupka E, et al. Genome-wide signatures of convergent evolution in echolocating mammals. Nature [Internet]. 2013 [cited 2017 Apr 6];502. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3836225/

5. Denoëud F, Carretero-Paulet L, Dereeper A, Droc G, Guyot R, Pietrella M, et al. The coffee genome provides insight into the convergent evolution of caffeine biosynthesis. Science. 2014; 345:1181–4. https://doi.org/10.1126/science.1255274 PMID: 25190796

6. Marvig RL, Sommer LM, Molin S, Johansen HK. Convergent evolution and adaptation of Pseudomonas aeruginosa within patients with cystic fibrosis. Nat. Genet. 2015; 47:57–64. https://doi.org/10.1038/ng.3148 PMID: 25401299

7. Farhat MR, Shapiro BJ, Kieser KJ, Sultana R, Jacobson KR, Victor TC, et al. Genomic Analysis Identifies Targets of Convergent Positive Selection in Drug Resistant Mycobacterium tuberculosis. Nat. Genet. 2013; 45:1183–9. https://doi.org/10.1038/ng.2747 PMID: 23995135

8. Osório NS, Rodrigues F, Gagneux S, Pedrosa J, Pinto-Carbo M, Castro AG, et al. Evidence for diversifying selection in a set of Mycobacterium tuberculosis genes in response to antibiotic- and nonantibiotic-related pressure. Mol. Biol. Evol. 2013; 30:1326–36. https://doi.org/10.1093/molbev/msr084 PMID: 23449927

9. Casali N, Nikolayevskyy V, Balabanova Y, Harris SR, Ignatyeva O, Kontsevaya I, et al. Evolution and transmission of drug resistant tuberculosis in a Russian population. Nat. Genet. 2014; 46:279–86. https://doi.org/10.1038/ng.2878 PMID: 24464101

10. Sandgren A, Strong M, Muthukrishnan P, Weiner BK, Church GM, Murray MB. Tuberculosis Drug Resistance Mutation Database. PLoS Med. [Internet]. 2009 [cited 2017 Apr 6]. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2637921/

11. Ramage HR, Connolly LE, Cox JS. Comprehensive Functional Analysis of Mycobacterium tuberculosis Toxin-Antitoxin Systems: Implications for Pathogenesis, Stress Responses, and Evolution. PLOS Genet. 2009; 5:e1000767. https://doi.org/10.1371/journal.pgen.1000767 PMID: 20011113

12. Robson J, McKenzie JL, Cursons R, Cook GM, Arcus VL. The vapBC operon from Mycobacterium smegmatis is an autoregulated toxin-antitoxin module that controls growth via inhibition of translation. J. Mol. Biol. 2009; 390:353–67. https://doi.org/10.1016/j.jmb.2009.05.006 PMID: 19445953

13. Gomez JE, McKinney JD. M. tuberculosis persistence, latency, and drug tolerance. Tuberc. Edinb. Scott. 2004; 94:29–44.

14. Uplekar S, Heym B, Fricourt V, Rougemont J, Cole ST. Comparative genomics of Esx genes from clinical isolates of Mycobacterium tuberculosis provides evidence for gene conversion and epitope variation. Infect. Immun. 2011; 79:4042–9. https://doi.org/10.1128/IAI.05344-11 PMID: 21807910

15. Garen CR, Cherney MM, Bergmann EM, James MNG. The molecular structure of Rv1873, a conserved hypothetical protein from Mycobacterium tuberculosis, at 1.38 Å resolution. Acta Crystallograph. Sect. F. Struct. Biol. Cryst. Commun. 2006; 62:1201–5.

16. Clinical Implications of Molecular Drug Resistance Testing for Mycobacterium Tuberculosis: A TBNET/RESIST-TB Consensus Statement [Internet]. PubMed J. [cited 2017 Apr 6]. Available from: https://ncbi.nlm.nih.gov/labs/articles/26688526/

17. Ando H, Miyoshi-Akiyama T, Watanabe S, Kirikae T. A silent mutation in mabA confers isoniazid resistance on Mycobacterium tuberculosis. Mol. Microbiol. 2014; 91:538–47. https://doi.org/10.1111/mmi.12476 PMID: 24354762

18. Agashe D, Martinez-Gomez NC, Drummond DA, Marx CJ. Good Codons, Bad Transcript: Large Reductions in Gene Expression and Fitness Arising from Synonymous Mutations in a Key Enzyme. Mol. Biol. Evol. 2013; 30:549–60. https://doi.org/10.1093/molbev/mss273 PMID: 23223712
19. Minch KJ, Rustad TR, Peterson EJR, Winkler J, Reiss DJ, Ma S, et al. The DNA-binding network of Mycobacterium tuberculosis. Nat. Commun. [Internet]. 2015 [cited 2017 Apr 6];6. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4301838/

20. Villarreal DO, Walters J, Lddy DJ, Yan J, Weiner DB. Multivalent TB vaccines targeting the esx gene family generate potent and broad cell-mediated immune responses superior to BCG. Hum. Vaccines Immunother. 2014; 10:2188–98.

21. Gordon SV, Brosch R, Billault A, Garnier T, Eiglmeier K, Cole ST. Identification of variable regions in the genomes of tubercle bacilli using bacterial artificial chromosome arrays. Mol. Microbiol. 1999; 32:643–55. PMID: 10320585

22. Skjøt RLV, Brock I, Arend SM, Munk ME, Theisen M, Ottenhoff THM, et al. Epitope Mapping of the Immunodominant Antigen TB10.4 and the Two Homologous Proteins TB10.3 and TB12.9, Which Constitute a Subfamily of the esat-6 Gene Family. Infect. Immun. 2002; 70:5446–53. https://doi.org/10.1128/IAI.70.10.5446-5453.2002 PMID: 12282629

23. Sirakova TD, Dubey VS, Kim H-J, Cynamon MH, Kolattukudy PE. The largest open reading frame (pk12) in the Mycobacterium tuberculosis genome is involved in pathogenesis and dimycoloyl-phthiocerol synthesis. Infect. Immun. 2003; 71:3794–801. https://doi.org/10.1128/IAI.71.7.3794-3801.2003 PMID: 12819062

24. Comas I, Borrell S, Roetzer A, Rose G, Malla B, Kato-Maeda M, et al. Whole-genome sequencing of rifampin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat. Genet. 2012; 44:106.

25. Grandjean L, Iwamoto T, Lithgow A, Gilman RH, Arikawa K, Nakanishi N, et al. The Association between Mycobacterium Tuberculosis Genotype and Drug Resistance in Peru. PLOS ONE. 2015; 10: e0126271. https://doi.org/10.1371/journal.pone.0126271 PMID: 25984723

26. Grandjean L, Gilman RH, Martin L, Soto E, Castro B, Lopez S, et al. Transmission of Multidrug-Resistant and Drug-Susceptible Tuberculosis within Households: A Prospective Cohort Study. PLOS Med. 2015; 12:e1001843. https://doi.org/10.1371/journal.pmed.1001843 PMID: 26103620

27. Moore DAJ, Evans CAW, Gilman RH, Caviedes L, Coronel J, Vivar A, et al. Rapid, Efficient Detection and Drug-susceptibility assay for the diagnosis of TB. N. Engl. J. Med. 2006; 355:1539–50. https://doi.org/10.1056/NEJMoa055524 PMID: 17035648

28. Caviedes L, Lee T-S, Gilman RH, Arikawa K, Nakanishi N, et al. The Association between Mycobacterium Tuberculosis Genotype and Drug Resistance in Peru. PLOS ONE. 2015; 10: e0126271. https://doi.org/10.1371/journal.pone.0126271 PMID: 25984723

29. Sirakova TD, Dubey VS, Kim H-J, Cynamon MH, Kolattukudy PE. The largest open reading frame (pk12) in the Mycobacterium tuberculosis genome is involved in pathogenesis and dimycoloyl-phthiocerol synthesis. Infect. Immun. 2003; 71:3794–801. https://doi.org/10.1128/IAI.71.7.3794-3801.2003 PMID: 12819062

30. Comas I, Borrell S, Roetzer A, Rose G, Malla B, Kato-Maeda M, et al. Whole-genome sequencing of rifampin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat. Genet. 2012; 44:106.

31. Grandjean L, Iwamoto T, Lithgow A, Gilman RH, Arikawa K, Nakanishi N, et al. The Association between Mycobacterium Tuberculosis Genotype and Drug Resistance in Peru. PLOS ONE. 2015; 10: e0126271. https://doi.org/10.1371/journal.pone.0126271 PMID: 25984723

32. Grandjean L, Gilman RH, Martin L, Soto E, Castro B, Lopez S, et al. Transmission of Multidrug-Resistant and Drug-Susceptible Tuberculosis within Households: A Prospective Cohort Study. PLOS Med. 2015; 12:e1001843. https://doi.org/10.1371/journal.pmed.1001843 PMID: 26103620

33. Moore DAJ, Evans CAW, Gilman RH, Caviedes L, Coronel J, Vivar A, et al. Rapid, Efficient Detection and Drug-susceptibility assay for the diagnosis of TB. N. Engl. J. Med. 2006; 355:1539–50. https://doi.org/10.1056/NEJMoa055524 PMID: 17035648

34. Caviedes L, Lee T-S, Gilman RH, Arikawa K, Nakanishi N, et al. The Association between Mycobacterium Tuberculosis Genotype and Drug Resistance in Peru. PLOS ONE. 2015; 10: e0126271. https://doi.org/10.1371/journal.pone.0126271 PMID: 25984723

35. Sirakova TD, Dubey VS, Kim H-J, Cynamon MH, Kolattukudy PE. The largest open reading frame (pk12) in the Mycobacterium tuberculosis genome is involved in pathogenesis and dimycoloyl-phthiocerol synthesis. Infect. Immun. 2003; 71:3794–801. https://doi.org/10.1128/IAI.71.7.3794-3801.2003 PMID: 12819062

36. Comas I, Borrell S, Roetzer A, Rose G, Malla B, Kato-Maeda M, et al. Whole-genome sequencing of rifampin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat. Genet. 2012; 44:106.

37. Grandjean L, Iwamoto T, Lithgow A, Gilman RH, Arikawa K, Nakanishi N, et al. The Association between Mycobacterium Tuberculosis Genotype and Drug Resistance in Peru. PLOS ONE. 2015; 10: e0126271. https://doi.org/10.1371/journal.pone.0126271 PMID: 25984723

Adaptive evolution in multidrug-resistant tuberculosis
38. Brown AC, Bryant JM, Einer-Jens en K, Holdstock J, Houniet DT, Chan JZM, et al. Rapid Whole-Genome Sequencing of Mycobacterium tuberculosis Isolates Directly from Clinical Samples. J. Clin. Microbiol. 2015; 53:2230–7. https://doi.org/10.1128/JCM.00486-15 PMID: 25972414

39. Schliep KP. phangorn: phylogenetic analysis in R. Bioinformatics. 2011; 27:592–3. https://doi.org/10.1093/bioinformatics/btq706 PMID: 21169378

40. Stamatakis A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies. Bioinforma. Oxf. Engl. 2014; 30:1312–3.

41. Efron B, Halloran E, Holmes S. Bootstrap confidence levels for phylogenetic trees. Proc. Natl. Acad. Sci. U. S. A. 1996; 93:13429–34. PMID: 8917608

42. Weniger T, Krawczyk J, Supply P, Niemann S, Harmsen D. MiRU-VNTRplus: a web tool for polyphasic genotyping of Mycobacterium tuberculosis complex bacteria. Nucleic Acids Res. 2010; 38:W326–31. https://doi.org/10.1093/nar/gkq351 PMID: 20457747

43. Jombart T, Devillard S, Balloux F. Discriminant analysis of principal components: a new method for the analysis of genetically structured populations. BMC Genet. 2010; 11:94. https://doi.org/10.1186/1471-2156-11-94 PMID: 20950446

44. Jombart T, Ahmed I. adegenet 1.3–1: new tools for the analysis of genome-wide SNP data. Bioinformatics. 2011; 27:3070–1. https://doi.org/10.1093/bioinformatics/btr521 PMID: 21926124

45. Galli T. dendextend: an R package for visualizing, adjusting and comparing trees of hierarchical clustering. Bioinforma. Oxf. Engl. 2015; 31:3718–20.

46. Kendall M, Colijn C. A tree metric using structure and length to capture distinct phylogenetic signals. Mol. Biol. Evol. 2016; 33:2735–43. https://doi.org/10.1093/molbev/msw124 PMID: 27343287

47. Kendall M, Colijn C. Mapping phylogenetic trees to reveal distinct patterns of evolution. bioRxiv. 2015;26641.

48. Stamatakis A. Phylogenetic models of rate heterogeneity: a high performance computing perspective. Parallel Distrib. Process. Symp. 2006 IPDPS 2006 20th Int. [Internet]. IEEE; 2006 [cited 2017 Apr 6]. p. 8–pp. Available from: http://ieeexplore.ieee.org/abstract/document/1639535/

49. Jombart T, Kendall ML, Almagro-Garcia J, Colijn C. treescape. 2015 [cited 2017 Apr 6]; Available from: http://spiral.imperial.ac.uk/handle/10044/1/30343